Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER VACCINES

Boosting dendritic cell nanovaccines

Nature Nanotechnology volume 17, pages 442–444 (2022)Cite this article

Subjects

A preclinical study reports a platform for the generation of dendritic cell-derived nanovesicles with enhanced immunostimulatory function, which demonstrate promising antitumoural activity in mouse models and might overcome some of the shortcomings of early-generation dendritic cell nanovaccines.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ASPIRE induces protective antitumour immunity in mice.

References

  1. Perez, C. R. & De Palma, M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat. Commun. 10, 1–10 (2019).

    Article  CAS  Google Scholar 

  2. Pitt, J. M. et al. Dendritic cell-derived exosomes for cancer therapy. J. Clin. Invest. 126, 1224–1232 (2016).

    Article  Google Scholar 

  3. Liu et al. Antigen Self-Presenting Nanovaccine with Immunosuppression Reversal (ASPIRE) for Personalized Cancer Immunotherapy. Nat. Nanotechnol. https://doi.org/10.1038/s41565-022-01084-6 (2022).

    Article  Google Scholar 

  4. Squadrito, M. L., Cianciaruso, C., Hansen, S. K. & De Palma, M. EVIR: Chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. Nat. Methods 15, 183–186 (2018).

    Article  CAS  Google Scholar 

  5. Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153–167 (2018).

    Article  CAS  Google Scholar 

  6. Brossart, P. The role of antigen spreading in the efficacy of immunotherapies. Clin. Cancer Res. 26, 4442–4447 (2020).

    Article  CAS  Google Scholar 

  7. Escudier, B. et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of the first phase 1 clinical trial. J. Transl. Med. 3, 1–13 (2005).

    Article  Google Scholar 

  8. Morse, M. A. et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 3, 1–8 (2005).

    Article  Google Scholar 

  9. Viaud, S. et al. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: A critical role of interferon-γ. J. Immunother. 34, 65–75 (2011).

    Article  Google Scholar 

  10. Besse, B. et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology 5, 1–13 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland

    Yahya Mohammadzadeh & Michele De Palma

  2. Agora Cancer Research Center, Lausanne, Switzerland

    Yahya Mohammadzadeh & Michele De Palma

  3. Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland

    Yahya Mohammadzadeh & Michele De Palma

Authors
  1. Yahya Mohammadzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michele De Palma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michele De Palma.

Ethics declarations

Competing interests

M.D.P. is an inventor on a patent application filed by EPFL (WO2017134100A1) on engineered dendritic cell vaccines. M.D.P. serves on the scientific advisory board of EVIR Therapeutics, a start-up focused on the development of engineered dendritic cell vaccines for cancer therapy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohammadzadeh, Y., De Palma, M. Boosting dendritic cell nanovaccines. Nat. Nanotechnol. 17, 442–444 (2022). https://doi.org/10.1038/s41565-022-01089-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41565-022-01089-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research